A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.

Tagrisso (osimertinib) - AstraZeneca

sunvozertinib (DZD9008) - Dizal Pharma

JIN-A02 - J Ints Bio

QLH11811 - Qilu Pharma

Semena (befotertinib) - InventisBio, Betta Pharma

Rui Bi Da (rezivertinib) - Beta Pharma

Ameile (aumolertinib) - Jiangsu Hansoh Pharma

BPI-361175 - Betta Pharma

Lazcluze (lazertinib) - J&J

HS-10375 - Jiangsu Hansoh Pharma

Ivesa (firmonertinib) - Allist, ArriVent

JS113 - Shanghai Junshi Biosci

BDTX-1535 - Black Diamond Therap

HS-10504 - Jiangsu Hansoh Pharma

TQB3804 - Sino Biopharm

BBT-207 - Bridge Biotherap

http://www.ncbi.nlm.nih.gov/pubmed/40153991

Chandragouda R Patil; Chandrakant S Gawli; Harun M Patel

Mar 29, 2025